HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HSTM
HealthStream, Inc.
HSTM's fundamentals are strong and it looks cheap: trading at 40x earnings, below its usual 50x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HSTM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
HSTM's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HSTM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 38x | $28.29 | — |
| Cheap | 40x | $27.80 | -1.7% |
| Current | 40x | $28.29 | — |
| Fair | 50x | $35.27 | +25% |
| Expensive | 97x | $67.62 | +139% |
Historical ranges are pointers, not guarantees.
HSTM's PE is in its cheap range at 40x. If earnings grow as analysts expect, today's price would be 38x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HSTM Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
HSTM has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HSTM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.74 | +6.3% |
| Q3 2026 | $0.70 | +2.9% |
| Q2 2026 | $0.72 | +7.5% |
| Q1 2026 | $0.67 | +6.3% |
| Q4 2025 | $0.61 | -7.6% |
| Q3 2025 | $0.68 | +4.6% |
| Q2 2025 | $0.67 | +14% |
| Q1 2025 | $0.63 | +8.6% |
| Q4 2024 | $0.66 | +32% |
HSTM has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HSTM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HSTM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.3M | +8.9% |
| Q2 2026 | $83.7M | +13% |
| Q1 2026 | $81.2M | +11% |
| Q4 2025 | $79.7M | +7.4% |
| Q3 2025 | $76.5M | +4.6% |
| Q2 2025 | $74.4M | +4% |
| Q1 2025 | $73.5M | +1% |
| Q4 2024 | $74.2M | +5.2% |
HSTM's revenue has grown year over year for 23 quarters in a row: $83M last quarter, up 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.9% | -2 points |
| Q2 2026 | 9.9% | +2 points |
| Q1 2026 | 9.3% | +3.3 points |
| Q4 2025 | 3% | -3.3 points |
| Q3 2025 | 9.9% | +1 points |
| Q2 2025 | 7.9% | +1.8 points |
| Q1 2025 | 6% | -1.9 points |
| Q4 2024 | 6.3% | +0.3 points |
HSTM has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over HSTM on cash flow, with more consistent year-over-year improvement.
HSTM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $17.1M | -4.8% |
| Q2 2026 | $12.5M | +363% |
| Q1 2026 | $26.4M | +1.4% |
| Q4 2025 | $13M | +19% |
| Q3 2025 | $17.9M | -4.8% |
| Q2 2025 | $2.7M | -57% |
| Q1 2025 | $26M | +29% |
| Q4 2024 | $11M | -19% |
HSTM's free cash flow has been positive every quarter for seven years: $69M over the past year, up 20% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HSTM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HSTM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +342K shares |
| 1 year | -0.5% | -155K shares |
| 3 years | -3.6% | -1.1M shares |
| 5 years | -6.4% | -2M shares |
| Available history | -8.5% | -2.8M shares |
HSTM has 30M diluted shares, down 0.5% from a year ago, with $14M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $2.6M |
| Q1 2026 | $6.7M |
| Q4 2025 | $5M |
| Q3 2025 | $6.9M |
| Q4 2024 | — |
| Q4 2023 | $7.3M |
| Q3 2023 | $1.6M |
HSTM spent $14M buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HSTM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.6x | Net Cash |
| Q3 2025 | -0.8x | Net Cash |
| Q2 2025 | -0.8x | Net Cash |
| Q1 2025 | -1.3x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
HSTM has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HSTM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.3 | Neutral |
| Stochastic | 34.3 | Neutral |
HSTM's weekly RSI is 48 (neutral) and its Stochastic is 34 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HSTM PE vs Healthcare Sector
| Metric | HSTM | Sector median | Relative |
|---|---|---|---|
| PE | 40x | 26x | 56% above |
| PE % | 19 | 29 | 10 pts below |
HSTM is trading at 40x earnings, a 56% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HSTM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.5 | 10% below |
| 20 week MA | $29.8 | 5% below |
| 50 week MA | $25.4 | 11% above |
| 100 week MA | $27.3 | 3.7% above |
| 200 week MA | $26.7 | 5.9% above |
HSTM has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
HSTM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.6 | $21.7 | -21% |
| 2021 | $21.7 | $26.1 | +20% |
| 2022 | $26.1 | $24.6 | -5.9% |
| 2023 | $24.6 | $27.0 | +9.9% |
| 2024 | $27.0 | $31.8 | +17% |
| 2025 | $31.8 | $23.6 | -26% |
| 2026 YTD | $23.6 | $28.3 | +20% |
HSTM has the edge over HIMS on returns for 2026, with the stronger performance.